Fostamatinib
- Generic Name
- Fostamatinib
- Brand Names
- Tavalisse, Tavlesse
- Drug Type
- Small Molecule
- Chemical Formula
- C23H26FN6O9P
- CAS Number
- 901119-35-5
- Unique Ingredient Identifier
- SQ8A3S5101
- Background
Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP . Fostamatinib has also been granted orphan drug status by the FDA .
Recently, fostamatinib has been identified as a potential therapeutic for controlling acute respiratory distress syndrome (ARDS) in patients with severe COVID-19 through its ability to modulate the SYK kinase.
- Indication
用于治疗对既往治疗反应不足的慢性免疫性血小板减少症（ITP）成年患者的血小板减少症。
- Associated Conditions
- Chronic immune thrombocytopenia
Study in Healthy Males to Assess Bioavailability of 4 Different Fostamatinib Tablets
- First Posted Date
- 2010-09-23
- Last Posted Date
- 2010-12-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 24
- Registration Number
- NCT01208155
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Not Responding.
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2010-09-09
- Last Posted Date
- 2014-04-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 923
- Registration Number
- NCT01197521
- Locations
- 🇬🇧
Research Site, Wirral, United Kingdom
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
- First Posted Date
- 2010-09-09
- Last Posted Date
- 2014-04-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 323
- Registration Number
- NCT01197755
- Locations
- 🇬🇧
Research Site, Wirral, United Kingdom
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Disease Modifying Anti-rheumatic Drug (DMARD) But Not Responding.
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2010-09-09
- Last Posted Date
- 2014-04-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 913
- Registration Number
- NCT01197534
- Locations
- 🇬🇧
Research Site, Swindon, United Kingdom
A Study to Assess the Safety, Tolerability, and Blood and Urine Drug Levels of Fostamatinib Disodium (FosD) in Healthy Japanese and White Subjects
- First Posted Date
- 2010-07-22
- Last Posted Date
- 2013-02-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 56
- Registration Number
- NCT01167868
- Locations
- 🇺🇸
Research Site, Glendale, California, United States
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...
- Conditions
- Carcinoma, Renal CellHead and Neck NeoplasmsCarcinoma, Non-Small-Cell LungColorectal NeoplasmsPheochromocytoma
- Interventions
- First Posted Date
- 2009-06-18
- Last Posted Date
- 2015-09-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 37
- Registration Number
- NCT00923481
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Open-Label, Multicenter Extension Study for Patients Completing Treatment Phase of a Rigel-Sponsored R935788 Studies
- First Posted Date
- 2008-12-09
- Last Posted Date
- 2014-06-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 624
- Registration Number
- NCT00805467
- Locations
- 🇷🇴
Research Site, Sibiu, Romania
Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma
- First Posted Date
- 2008-11-25
- Last Posted Date
- 2016-09-19
- Lead Sponsor
- Rigel Pharmaceuticals
- Target Recruit Count
- 18
- Registration Number
- NCT00798096
- Locations
- 🇨🇦
Research Site, Toronto, Ontario, Canada
Efficacy and Safety Study of R935788 Tablets to Treat Systemic Lupus Erythematosus
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-09-16
- Last Posted Date
- 2012-04-30
- Lead Sponsor
- Rigel Pharmaceuticals
- Registration Number
- NCT00752999
Pilot Study of Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP)
- Conditions
- Purpura, Thrombocytopenic, Idiopathic
- Interventions
- First Posted Date
- 2008-06-27
- Last Posted Date
- 2016-06-03
- Lead Sponsor
- Rigel Pharmaceuticals
- Target Recruit Count
- 18
- Registration Number
- NCT00706342
- Locations
- 🇺🇸
Research Site, Cleveland, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.